Scynexis (SCYX) Asset Writedowns and Impairment (2015 - 2016)
Scynexis' (SCYX) quarterly Asset Writedowns and Impairment came in at $111000.0 in Q1 2016, down 91.78% quarter-over-quarter from $1.3 million in Q2 2015.
Powered by 
Analysis
Scynexis (SCYX) Asset Writedowns and Impairment (2015 - 2016) Analysis & Trends
Scynexis (SCYX) has reported Asset Writedowns and Impairment for 2 consecutive years, with $111000.0 the latest figure, recorded in Q1 2016.
- For the quarter ending Q1 2016, Asset Writedowns and Impairment changed N/A year-over-year to $111000.0; the trailing twelve-month figure through Dec 2016 stood at $111000.0 (down 91.78% YoY), and the FY2023 full-year result was $14.6 million, changed N/A from the prior year.
- Asset Writedowns and Impairment fell to $111000.0 in Q1 2016 per SCYX's latest filing, from $1.3 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.3 million in Q2 2015 and bottomed at $111000.0 in Q1 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |